Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.
Prescient Therapeutics Limited has issued 21.78 million unquoted options under its employee incentive scheme, exercisable at A$0.10 and expiring on 17 November 2029. The move is designed to align staff incentives with long-term shareholder value and supports the company’s efforts to retain and motivate key employees as it advances its oncology drug development pipeline.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is an ASX-listed biotechnology company focused on developing cancer therapies. The company operates in the biopharmaceutical sector, leveraging targeted and personalised medicine approaches to address unmet needs in oncology markets.
Average Trading Volume: 1,839,131
Technical Sentiment Signal: Buy
Current Market Cap: A$110.4M
See more data about PTX stock on TipRanks’ Stock Analysis page.